©2024 Stanford Medicine
Blood Pressure Lowering in Acute Stroke Trial
Not Recruiting
Trial ID: NCT01400256
Purpose
The investigators hope to show that valsartan can be used safely in the setting of acute
stroke to lower elevated blood pressure. There are novel properties of this class of drug (an
angiotensive-receptor blocker or ARB), and promising human and animal data, that would
suggest this drug can be safely used to lower blood pressure in the setting of acute stroke
without compromising brain blood flow (i.e. cerebral perfusion). If this is proved to be the
case, this compound could potentially be used routinely in this setting, with the hope of
improving outcome. This pilot study may pave the way for a larger randomized trial looking at
outcome measures in stroke patients. Further, a positive result in the this pilot study will
serve as proof of concept that ARBs maintain cerebral perfusion while decreasing blood
pressure, an overall favorable property.
Official Title
The Use of Valsartan for the Management of Blood Pressure in Acute Stroke: Affects on Cerebral Blood Flow
Stanford Investigator(s)
Gregory W. Albers, MD
Coyote Foundation Professor and Professor, by courtesy, of Neurosurgery
Eligibility
Inclusion Criteria:
1. Men and non-pregnant women over age 18 who have had an acute ischemic stroke referable
to the anterior circulation, as diagnosed by one of more of the following: clinical
judgment, head CT, and/or MR imaging [i.e. a positive diffusion-weighted imaging (DWI)
abnormality].
2. Clinical syndrome not likely to represent transient ischemic attack (TIA) or other
non-stroke etiology
3. Patient must be neurologically stable at the time of first MRI scan (i.e. stable NIH
Stroke Scale score).
4. Initial MRI scan obtainable within 48 hours of symptom onset.
5. A pre-existing diagnosis of hypertension, either treated or untreated.
6. Average of two mean arterial blood pressures (separated by at least five minutes) at
time of initial MRI scan ≥ 110.
Exclusion Criteria:
1. Patients who have taken an angiotensin-converting enzyme (ACE) inhibitor or
angiotensin receptor blocker (ARB) within seven (7) days of admission.
2. Patients who received intravenous or intra-arterial r-TPA for their current symptoms,
or those who underwent mechanical thrombolysis.
3. Patients with hemorrhagic strokes, as seen on the initial head CT.
4. Patients with stroke-like symptoms, but no demonstrable lesion on DWI, or a DWI lesion
< 2 cm in diameter (greatest dimension).
5. Patients with high-grade (>70%) internal carotid artery stenosis or occlusion
ipsilateral to the current stroke.
6. Patients with high-grade aortic or mitral stenosis.
7. Patients with a previous adverse reaction to valsartan or other ARBs.
8. Patients with contraindications for MRI, including pacemakers, claustrophobia, or
severe obesity.
9. Patients who are medically unstable for MR imaging, as determined by the treating
team.
10. Patients with a severe co-existing disease that may interfere with the conduct of the
study.
11. Patients receiving investigational drug therapies.
12. Informed consent cannot be obtained from the patient or their legal representative.
Intervention(s):
drug: Valsartan
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305